Cytoreductive Nephrectomy May Improve Survival in ICI-Treated mRCC
In the era of immune checkpoint inhibitors, cytoreductive nephrectomy retains an important role in mRCC in carefully selected patients, according to investigators.
In the era of immune checkpoint inhibitors, cytoreductive nephrectomy retains an important role in mRCC in carefully selected patients, according to investigators.
Possible reasons for the survival disparity include differences in obesity and smoking incidence among Black men younger than 50 years.
Patients with PD-L1 expression at initial transurethral resection for bladder cancer were more likely to harbor invasive disease, according to investigators.
Validation of the cytokine markers within the entire NIVOREN study is ongoing.
Neoadjuvant enfortumab vedotin demonstrated promising initial results in a small number of cisplatin-ineligible patients with muscle-invasive bladder cancer, according to investigators.
Early-salvage radiation therapy was associated with reduced risks for biochemical recurrence and metastasis, compared with expectant management.
Screening for sarcopenia may assist in identifying patients at high risk for increased perioperative morbidity, according to investigators.
Patients receiving immunotherapy had a more durable immune response to vaccination, compared with patients receiving chemotherapy or targeted therapy.
Adjuvant mitotane does not improve outcomes in patients with adrenocortical carcinoma at low or intermediate risk of relapse after surgery.
New findings could inform personalized therapeutic strategies for patients with renal cell carcinoma, according to investigators.